CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects

Journal of Experimental & Clinical Cancer Research

Zhengtang Chen³  Bo Zhu³  Yan Wang²  Liang Zhang¹  Wenlei Zhuo³ 

[1] Department of Environmental Hygiene, College of Preventive Medicine, Third Military Medical University, Chongqing, China;Institute of Respiratory Diseases,Xinqiao Hospital, Third Military Medical University, Chongqing, China;Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China

关键词: Polymorphism;    Meta-analysis;    Susceptibility;    Malignancy;    Acute myeloid leukemia;    CYP1A1 MspI;   

Others  :  826214
DOI  :  10.1186/1756-9966-31-62

 received in 2012-06-26, accepted in 2012-07-13,  发布年份 2012

【 摘 要 】

Background

Evidence indicates that CYP1A1 MspI polymorphism might be a possible risk factor for several malignancies. A growing body of literature has been devoted to the association of CYP1A1 MspI polymorphism with acute myeloid leukemia (AML). However, the results remain conflicting. The aim of the present study was to derive a more precise estimation of the relationship.

Methods

Meta-analyses assessing the association of CYP1A1 MspI variation with AML were conducted and subgroup analyses on ethnicity and age groups were further performed. Eligible studies were identified for the period up to May 2012.

Results

A total of ten case–control studies including 1330 cases and 3688 controls were selected for analysis. The overall data failed to indicate a significant association of CYP1A1 MspI polymorphism with AML risk (C vs T: OR = 1.13; 95%CI = 0.87-1.48; CC vs TT: OR = 1.72; 95%CI = 0.99-3.01; CC + TC vs TT: OR = 1.16; 95%CI = 0.86-1.55). In subgroup analysis stratified by ethnicity, significant AML risk was shown among Asians (CC + TC vs TT: OR = 1.33; 95%CI = 1.09-1.62) but not Caucasians or mixed races. In subgroup analysis regarding age groups, no associations were observed in either the childhood AML or the adult AML subgroups.

Conclusion

The results of the present study suggested that CYP1A1 MspI polymorphism might be a risk factor for AML among Asians. Further investigations are needed to confirm the conclusions.

【 授权许可】

   
2012 Zhuo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

Figure 5 .

【 参考文献 】

• [1]Ilhan G, Karakus S, Andic N: Risk factors and primary prevention of acute leukemia. Asian Pacific journal of cancer prevention : APJCP 2006, 7:515-517.
• [2]Yan J, Yin M, Dreyer ZE, Scheurer ME, Kamdar K, Wei Q, Okcu MF: A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatric blood & cancer 2012, 58:513-518.
• [3]Ye Z, Song H: Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990) 2005, 41:980-989.
• [4]Wang L, Yin F, Xu X, Hu X, Zhao D: X-Ray Repair Cross-Complementing Group 1 (XRCC1) Genetic Polymorphisms and Risk of Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis. PloS one 2012, 7:e34897.
• [5]Yu K, Zhang J, Dou C, Gu S, Xie Y, Mao Y, Ji C: Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. European journal of human genetics : EJHG 2010, 18:370-378.
• [6]Boffetta P: Biomarkers in cancer epidemiology: an integrative approach. Carcinogenesis 2010, 31:121-126.
• [7]Guengerich FP, Shimada T: Activation of procarcinogens by human cytochrome P450 enzymes. Mutation research 1998, 400:201-213.
• [8]Zhou SF, Liu JP, Chowbay B: Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug metabolism reviews 2009, 41:89-295.
• [9]Munafo MR, Clark TG, Flint J: Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry research 2004, 129:39-44.
• [10]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [11]Yang Y, Tian Y, Jin X, Yan C, Jiang F, Zhang Y, Tang J, Shen X: A case-only study of interactions between metabolic enzyme polymorphisms and industrial pollution in childhood acute leukemia. Environmental toxicology and pharmacology 2009, 28:161-166.
• [12]Pelloso LA, Da Silva ID, De Souza NC, Yamamoto M, Botelho CA, Chauffaille Mde L: CYP1A1 polymorphisms modify overall survival in acute myeloid leukemia patients. Leukemia & lymphoma 2007, 48:1211-1215.
• [13]Barragan E, Collado M, Cervera J, Martin G, Bolufer P, Roman J, Sanz MA: The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leukemia research 2007, 31:947-953.
• [14]Voso MT, D'Alo F, Gumiero D, Guidi F, Hohaus S, Leone G: The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 2005, 90:982-984.
• [15]Infante-Rivard C, Krajinovic M, Labuda D, Sinnett D: Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Quebec, Canada). Cancer causes & control : CCC 2000, 11:547-553.
• [16]Liu QX, Chen HC, Liu XF, Cao YF, Zhang J, Liu J: Study on the relationship between polymorphisms of Cyp1A1, GSTM1, GSTT1 genes and the susceptibility to acute leukemia in the general population of Hunan province. Zhonghua liu xing bing xue za zhi 2005, 26:975-979.
• [17]Chen HC, Hu WX, Liu QX, Li WK, Chen FZ, Rao ZZ, Liu XF, Luo YP, Cao YF: Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2008, 17:251-258.
• [18]Bolufer P, Collado M, Barragan E, Calasanz MJ, Colomer D, Tormo M, Gonzalez M, Brunet S, Batlle M, Cervera J, Sanz MA: Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. British journal of haematology 2007, 136:590-596.
• [19]Bolufer P, Collado M, Barragan E, Cervera J, Calasanz MJ, Colomer D, Roman-Gomez J, Sanz MA: The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica 2007, 92:308-314.
• [20]Kim HN, Kim NY, Yu L, Tran HT, Kim YK, Lee IK, Shin MH, Park KS, Choi JS, Kim HJ: Association of GSTT1 polymorphism with acute myeloid leukemia risk is dependent on smoking status. Leukemia & lymphoma 2012, 53:681-687.
• [21]Bonaventure A, Goujon-Bellec S, Rudant J, Orsi L, Leverger G, Baruchel A, Bertrand Y, Nelken B, Pasquet M, Michel G, et al.: Maternal smoking during pregnancy, genetic polymorphisms of metabolic enzymes, and childhood acute leukemia: the ESCALE study (SFCE). Cancer causes & control : CCC 2012, 23:329-345.
• [22]Yamaguti GG, Lourenco GJ, Costa FF, Lima CS: High risk of 'de novo' acute myeloid leukaemia in individuals with cytochrome P450 A1 (CYP1A1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) gene defects. European journal of haematology 2009, 83:270-272.
• [23]Majumdar S, Mondal BC, Ghosh M, Dey S, Mukhopadhyay A, Chandra S, Dasgupta UB: Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2008, 17:125-132.
• [24]Jiang L, Chen M, Qin G: Association between the polymorphisms of cytochrome P4501A1 and glutathione S-transferase M1, T1 Genes and acute myeloid leukemia in Guangxi. Guangxi Medical Journal 2008, 30:464-466.
• [25]Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U: Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. American journal of hematology 2006, 81:162-170.
• [26]D'Alo F, Voso MT, Guidi F, Massini G, Scardocci A, Sica S, Pagano L, Hohaus S, Leone G: Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. Haematologica 2004, 89:664-670.
• [27]Balta G, Yuksek N, Ozyurek E, Ertem U, Hicsonmez G, Altay C, Gurgey A: Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. American journal of hematology 2003, 73:154-160.
• [28]Clavel J, Bellec S, Rebouissou S, Menegaux F, Feunteun J, Bonaiti-Pellie C, Baruchel A, Kebaili K, Lambilliotte A, Leverger G, et al.: Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2005, 14:531-540.
• [29]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
• [30]Tobias A: Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 1999, 8:15-17.
• [31]Zhuo WL, Wang Y, Zhuo XL, Zhu B, Zhu Y, Chen ZT: Polymorphisms of CYP1A1 and GSTM1 and laryngeal cancer risk: evidence-based meta-analyses. Journal of cancer research and clinical oncology 2009, 135:1081-1090.
• [32]Shaik AP, Jamil K, Das P: CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. Urology journal 2009, 6:78-86.
• [33]Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK: CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. Journal of experimental & clinical cancer research : CR 2011, 30:99. BioMed Central Full Text
• [34]Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF: Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis. Molecular biology reports 2012.
• [35]Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, Chen ZT: Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Archives of medical research 2009, 40:169-179.
• [36]Sergentanis TN, Economopoulos KP: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast cancer research and treatment 2010, 122:459-469.
• [37]Zheng Y, Wang JJ, Sun L, Li HL: Association between CYP1A1 polymorphism and colorectal cancer risk: a meta-analysis. Molecular biology reports 2012, 39:3533-3540.
• [38]Guo R, Guo X: Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk. Tumour biology. the journal of the International Society for Oncodevelopmental Biology and Medicine 2012.
• [39]Zhang YD, Tan LN, Zhang XL, Wei HY, Xiong H, Hu Q: Meta-analysis of cytochrome P4501A1 MspI gene polymorphism and childhood acute leukemia. Biomedical and environmental sciences : BES 2011, 24:683-687.
• [40]Bierenbaum J, Davidoff AJ, Ning Y, Tidwell ML, Gojo I, Baer MR: Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience. Leukemia research 2012, 36:140-145.
• [41]Larfors G, Hallbook H, Simonsson B: Parental age, family size, and offspring's risk of childhood and adult acute leukemia. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012.
• [42]Juhl-Christensen C, Ommen HB, Aggerholm A, Lausen B, Kjeldsen E, Hasle H, Hokland P: Genetic and epigenetic similarities and differences between childhood and adult AML. Peditric blood & cancer 2012, 58:525-531.